




RECEIVED
CENTRAL FAX CENTER

DEC 22 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/509,633	Applicant: Jean-Claude Arnould
371 Filing Date: 09/29/2004	Attorney Docket No.: 100467-1P US
Examiner: Grazier, Nyeemah	Group Art Unit : 1626
Customer No.: 44992	Confirmation No.: 4294
Title: INDOLE DERIVATIVES HAVING ANTI-ANGIOGENETIC ACTIVITY	

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on 22 December 2005



Signature
Lucy Padget

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT

Sir:

In response to the Non-Final Office Action dated 12/13/2005, please amend the above-identified application as follows:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims begin on page 3 of this paper.

Remarks/Arguments begin on page 8 of this paper.

AstraZeneca R&D Boston
A business unit of AstraZeneca Pharmaceuticals LP
35 Gatehouse Drive
Waltham MA 02451

Tel +1 781-839-4000
Fax +1 781-839-4500

Page 1 of 9